AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2959900 — intervention group
Group type: COMPARATOR
Intervention: Nebulized normal saline solution
Number of subjects: 79
Study 31880171 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic planning (involving a non-smoking partner)
Number of subjects: 176
Study 31880171 — intervention group
Group type: COMPARATOR
Intervention: Individual planning
Number of subjects: 176
Study 29969742 — intervention group
Group type: EXPERIMENTAL
Intervention: uTLIF with PMMA augmentation
Number of subjects: 50
Study 29969742 — intervention group
Group type: COMPARATOR
Intervention: standard uTLIF
Number of subjects: 50
Study 27838680 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative antimicrobial therapy
Number of subjects: 100
Study 27838680 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 100
Study 26281326 — intervention group
Group type: EXPERIMENTAL
Intervention: Full face mask (Group F)
Number of subjects: 50
Study 26281326 — intervention group
Group type: COMPARATOR
Intervention: Helmet (Group H)
Number of subjects: 50
Study 26281326 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group F and Group H)
Number of subjects: 50
Study 24311880 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot nature dietary intervention with co‐supplemented hemp seed and evening primrose oils
Number of subjects: 100
Study 24311880 — intervention group
Group type: EXPERIMENTAL
Intervention: Co‐supplemented hemp seed and evening primrose oils
Number of subjects: 100
Study 24311880 — intervention group
Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 100
Study 21570642 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 g casein hydrolysate
Number of subjects: 13
Study 21570642 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g casein hydrolysate
Number of subjects: 13
Study 21570642 — intervention group
Group type: COMPARATOR
Intervention: 0 g casein hydrolysate (control)
Number of subjects: 13
Study 17653855 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended protocol (96 cores excised)
Number of subjects: 266
Study 17653855 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol (24 cores obtained)
Number of subjects: 266
Study 17653855 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended protocol
Number of subjects: 266
Study 17653855 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol
Number of subjects: 266
Study 17653855 — intervention group
Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 266
Study 16239622 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 12
Study 16239622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12968845 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-treated catheters
Number of subjects: 139
Study 12968845 — intervention group
Group type: COMPARATOR
Intervention: Control catheters
Number of subjects: 139
Study 11101474 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh yogurt (500 g/d for 15 days)
Number of subjects: 24
Study 11101474 — intervention group
Group type: COMPARATOR
Intervention: Heated yogurt (500 g/d for 15 days)
Number of subjects: 24
Study 8704064 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal administration of 20 IU AVP
Number of subjects: 15
Study 8704064 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of 1.5 IU AVP
Number of subjects: 15
Study 8704064 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 15
Study 1288668 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of physostigmine and deprenyl
Number of subjects: 16
Study 6748070 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical inactivity and smoking
Number of subjects: 0
Study 6748070 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive men and smokers
Number of subjects: 0
Study 6748070 — intervention group
Group type: COMPARATOR
Intervention: Age, Type A behavior pattern, blood pressure, serum cholesterol, serum high-density lipoprotein, and obesity
Number of subjects: 0
Study 31644556 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygiene and foot-care intervention (training in foot hygiene, skin care, bandaging, exercises, use of socks and shoes)
Number of subjects: 0
Study 31644556 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygiene and foot-care intervention
Number of subjects: 0
Study 31644556 — intervention group
Group type: COMPARATOR
Intervention: Control (delayed intervention group)
Number of subjects: 0
Study 29750632 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP (6 additional cycles)
Number of subjects: 862
Study 29750632 — intervention group
Group type: COMPARATOR
Intervention: Burkitt protocol (6 blocks)
Number of subjects: 862
Study 29750632 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP (4 additional cycles)
Number of subjects: 862
Study 29750632 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP with additional rituximab (4 additional cycles)
Number of subjects: 862
Study 26908242 — intervention group
Group type: EXPERIMENTAL
Intervention: Early reversal of defunctioning ileostomy
Number of subjects: 26
Study 26908242 — intervention group
Group type: COMPARATOR
Intervention: Late reversal of defunctioning ileostomy
Number of subjects: 26
Study 25406780 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin care protocol every 6 hours (gentle cleanser, moisturizer, skin protectant/barrier)
Number of subjects: 99
Study 25406780 — intervention group
Group type: COMPARATOR
Intervention: Skin care protocol every 12 hours (gentle cleanser, moisturizer, skin protectant/barrier)
Number of subjects: 99
Study 23176104 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient CR with resistance training and special balance training (5 d/wk)
Number of subjects: 173
Study 23176104 — intervention group
Group type: COMPARATOR
Intervention: Usual cardiac rehabilitation (CG)
Number of subjects: 173
Study 20370378 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivoglitazone 1 mg
Number of subjects: 441
Study 20370378 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivoglitazone 2 mg
Number of subjects: 441
Study 20370378 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivoglitazone 3 mg
Number of subjects: 441
Study 20370378 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg
Number of subjects: 441
Study 20370378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study 18034867 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starches (HES) 130/0.4, 500 ml infusion over 15 minutes
Number of subjects: 24
Study 15909194 — intervention group
Group type: EXPERIMENTAL
Intervention: 111In-DOTA-lanreotide (111In-DOTA-LAN)
Number of subjects: 18
Study 15909194 — intervention group
Group type: EXPERIMENTAL
Intervention: 111In-DOTA-D: Phe1-Tyr3-octreotide (111In-DOTA-TOC)
Number of subjects: 18
Study 15909194 — intervention group
Group type: COMPARATOR
Intervention: 18F-fluorodeoxyglucose (FDG) PET
Number of subjects: 18
Study 11843735 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 0
Study 11843735 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 0
Study 10512243 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbiturate anesthesia during fasting (F+B)
Number of subjects: 8
Study 10512243 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbiturate anesthesia during nonfasting (nonF+B)
Number of subjects: 8
Study 10512243 — intervention group
Group type: COMPARATOR
Intervention: Fasting (F)
Number of subjects: 8
Study 10512243 — intervention group
Group type: COMPARATOR
Intervention: Nonfasting (nonF)
Number of subjects: 8
Study 8746602 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg lisinopril once a day between 7 p.m. and 11 p.m.
Number of subjects: 66
Study 8746602 — intervention group
Group type: EXPERIMENTAL
Intervention: Trough-to-peak ratio
Number of subjects: 66
Study 8746602 — intervention group
Group type: EXPERIMENTAL
Intervention: Median trough-to-peak ratio
Number of subjects: 66
Study 8746602 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface ratio
Number of subjects: 66
Study 2030195 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual plus hotline
Number of subjects: 1813
Study 2030195 — intervention group
Group type: COMPARATOR
Intervention: Manual only
Number of subjects: 1813
Study 7047579 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C received placebo tablets and rinsed with folate MW twice daily for 1 min
Number of subjects: 30
Study 7047579 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B received placebo MW and one 5 mg folate tablet daily
Number of subjects: 30
Study 7047579 — intervention group
Group type: COMPARATOR
Intervention: Control Group A received placebo mouthwash (MW) and placebo tablets
Number of subjects: 30
Study 30251088 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Calorie Ketogenic Diet (VLCKD)
Number of subjects: 178
Study 30251088 — intervention group
Group type: COMPARATOR
Intervention: Very Low Calorie Diet (VLCD)
Number of subjects: 178
Study 27840301 — intervention group
Group type: EXPERIMENTAL
Intervention: teriparatide 20‐mcg SC daily
Number of subjects: 94
Study 27840301 — intervention group
Group type: EXPERIMENTAL
Intervention: denosumab 60‐mg SC every 6 months
Number of subjects: 94
Study 27840301 — intervention group
Group type: EXPERIMENTAL
Intervention: combined teriparatide/denosumab
Number of subjects: 94
Study 26222356 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pharmacotherapy and lidocaine block (Group II)
Number of subjects: 13
Study 26222356 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (Group I)
Number of subjects: 13
Study 24691140 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced computed tomography (DCE-CT)
Number of subjects: 12
Study 22540188 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T/3TC-based cART
Number of subjects: 650
Study 22540188 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline BMI
Number of subjects: 650
Study 22540188 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower baseline hemoglobin
Number of subjects: 650
Study 22540188 — intervention group
Group type: COMPARATOR
Intervention: No lactic acidosis symptoms
Number of subjects: 650
Study 19179298 — intervention group
Group type: EXPERIMENTAL
Intervention: synthetic salmon calcitonin (ssCT)
Number of subjects: 36
Study 19179298 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant salmon calcitonin (rsCT)
Number of subjects: 36
Study 19179298 — intervention group
Group type: COMPARATOR
Intervention: ssCT and rsCT
Number of subjects: 36
Study 17524724 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention applied to 13 randomly selected schools
Number of subjects: 1168
Study 17524724 — intervention group
Group type: EXPERIMENTAL
Intervention: Food taken as a proxy measure
Number of subjects: 1168
Study 16018807 — intervention group
Group type: EXPERIMENTAL
Intervention: VOCs analysis in NSCLC patients post-surgery
Number of subjects: 0
Study 16018807 — intervention group
Group type: EXPERIMENTAL
Intervention: VOCs analysis in NSCLC patients
Number of subjects: 0
Study 16018807 — intervention group
Group type: COMPARATOR
Intervention: VOCs analysis in healthy smokers and non-smokers
Number of subjects: 0
Study 16018807 — intervention group
Group type: COMPARATOR
Intervention: VOCs analysis in patients with COPD
Number of subjects: 0
Study 15463829 — intervention group
Group type: EXPERIMENTAL
Intervention: Creon 10,000 Minimicrospheres
Number of subjects: 59
Study 15463829 — intervention group
Group type: COMPARATOR
Intervention: Creon 8,000 microspheres
Number of subjects: 59
Study 10527999 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic sonography (nuchal translucency measurement at 10‐14 weeks and second trimester targeted ultrasound including fetal echocardiography)
Number of subjects: 153
Study 10527999 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic sonography
Number of subjects: 153
Study 8824685 — intervention group
Group type: COMPARATOR
Intervention: Lacidipine-based treatment (SHELL trial)
Number of subjects: 0
Study 8824685 — intervention group
Group type: COMPARATOR
Intervention: Lacidipine-based treatment (ELSA trial)
Number of subjects: 0
Study 2252400 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage (10 minute massage to the back)
Number of subjects: 28
Study 2252400 — intervention group
Group type: COMPARATOR
Intervention: Control (10 minute visit without massage)
Number of subjects: 28
Study 2252400 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 28
Study 2252400 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study 6783420 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic polypeptide infusion at 1 pmol kg‐1 min‐1
Number of subjects: 17
Study 6783420 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic polypeptide infusion at 4 pmol kg‐1 min‐1
Number of subjects: 17
Study 6783420 — intervention group
Group type: COMPARATOR
Intervention: Control (no pancreatic polypeptide infusion)
Number of subjects: 17
Study 6783420 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic polypeptide infusion
Number of subjects: 17
Study 31200985 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Planned Outreach, Intervention, Naloxone, and Treatment (POINT)
Number of subjects: 0
Study 31200985 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 30665020 — intervention group
Group type: EXPERIMENTAL
Intervention: Promoting First Relationships® (PFR) home visitation program
Number of subjects: 247
Study 30665020 — intervention group
Group type: COMPARATOR
Intervention: Resource and referral control condition
Number of subjects: 247
Study 29083222 — intervention group
Group type: EXPERIMENTAL
Intervention: Growing Pro‐Social (GPS) program
Number of subjects: 254
Study 29083222 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 254
Study 25295964 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based learning module and small-group debriefing
Number of subjects: 499
Study 23784600 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg daily)
Number of subjects: 0
Study 23784600 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic aspirin use
Number of subjects: 0
Study 23784600 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle including appropriate diet
Number of subjects: 0
Study 21635618 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous PRP injections
Number of subjects: 14
Study 21635618 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injections
Number of subjects: 14
Study 19543672 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.3 mg/kg body weight twice daily)
Number of subjects: 40
Study 17626054 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock wave therapy (SWT)
Number of subjects: 948
Study 12677620 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine 2.5 mg and fentanyl 25 microgram with epinephrine 100 microgram (Group BFE)
Number of subjects: 108
Study 12677620 — intervention group
Group type: COMPARATOR
Intervention: Control group: Intrathecal bupivacaine 2.5 mg and fentanyl 25 microgram without epinephrine (Group BF)
Number of subjects: 108
Study 12677620 — intervention group
Group type: EXPERIMENTAL
Intervention: Group BFE
Number of subjects: 108
Study 12677620 — intervention group
Group type: COMPARATOR
Intervention: Group BF
Number of subjects: 108
Study 12677620 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 108
Study 11153636 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethics consultation offered
Number of subjects: 74
Study 11153636 — intervention group
Group type: COMPARATOR
Intervention: Ethics consultation not offered
Number of subjects: 74
Study 9558774 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin (600 mg/day x 3/day), Amoxicillin (1 g x 2/day), Omeprazole (40 mg/day) for 2 weeks (protocol A)
Number of subjects: 23
Study 9558774 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin (600 mg/day x 3/day), Erythromycin‐ethylsuccinate (600 mg x 3/day), Omeprazole (40 mg/day) for 2 weeks (protocol B)
Number of subjects: 23
Study 1531926 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg/day for 3 months
Number of subjects: 85
Study 1531926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 4020412 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant doxorubicin (Adriamycin)
Number of subjects: 90
Study 4020412 — intervention group
Group type: COMPARATOR
Intervention: Nonrandomized control group
Number of subjects: 90
Study 31027480 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual withdrawal of remifentanil
Number of subjects: 34
Study 31027480 — intervention group
Group type: COMPARATOR
Intervention: Abrupt discontinuation of remifentanil
Number of subjects: 34
Study 30554184 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical vancomycin treatment group (257 patients)
Number of subjects: 2632
Study 30554184 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical vancomycin treatment group
Number of subjects: 2632
Study 27355810 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicaid patients
Number of subjects: 600000
Study 27355810 — intervention group
Group type: COMPARATOR
Intervention: Privately insured patients
Number of subjects: 600000
Study 27355810 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicaid appointments with nonphysician providers
Number of subjects: 600000
Study 27355810 — intervention group
Group type: COMPARATOR
Intervention: Private insurance appointments with nonphysician providers
Number of subjects: 600000
Study 27355810 — intervention group
Group type: EXPERIMENTAL
Intervention: Wait times for new Medicaid patients
Number of subjects: 600000
Study 27355810 — intervention group
Group type: COMPARATOR
Intervention: Wait times for new privately insured patients
Number of subjects: 600000
Study 25373012 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination inositol and glucomannan
Number of subjects: 40
Study 25373012 — intervention group
Group type: COMPARATOR
Intervention: Inositol
Number of subjects: 40
Study 25373012 — intervention group
Group type: COMPARATOR
Intervention: Glucomannan
Number of subjects: 40
Study 22114108 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination and controlled ovarian stimulation (IUI‐COS)
Number of subjects: 253
Study 22114108 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (EM)
Number of subjects: 253
Study 19885850 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice (200 mL PJ/day) for 3 days before surgery
Number of subjects: 63
Study 19885850 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnuts (35 g walnuts/day) for 3 days before surgery
Number of subjects: 63
Study 19885850 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 63
Study 19253503 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Dextran-40 in NSS
Number of subjects: 104
Study 19253503 — intervention group
Group type: COMPARATOR
Intervention: 10% Haes-steril in NSS
Number of subjects: 104
Study 19253503 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 104
Study 15564311 — intervention group
Group type: EXPERIMENTAL
Intervention: hylan G-F 20
Number of subjects: 255
Study 15564311 — intervention group
Group type: COMPARATOR
Intervention: appropriate care without hylan G-F 20
Number of subjects: 255
Study 12618280 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated Fatty Acids (SFA diet)
Number of subjects: 162
Study 12618280 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated Fatty Acids (MUFA diet)
Number of subjects: 162
Study 12618280 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (3.6 g/day)
Number of subjects: 162
Study 12618280 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 162
Study 12618280 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids supplementation
Number of subjects: 162
Study 10546927 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam, 15 mg/day
Number of subjects: 0
Study 10546927 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (positive control)
Number of subjects: 0
Study 8668411 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration therapy (ORT)
Number of subjects: 0
Study 8668411 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) rehydration treatment
Number of subjects: 0
Study 8668411 — intervention group
Group type: COMPARATOR
Intervention: Oral rehydration solutions (ORSs) of different sodium content
Number of subjects: 0
Study 8668411 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient settings
Number of subjects: 0
Study 1853156 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-gram 5-aminosalicylic acid retention enema (Mesasal) administered for seven consecutive nights and one additional enema on the eighth night
Number of subjects: 10
Study 6882699 — intervention group
Group type: EXPERIMENTAL
Intervention: New tricyclic antidepressant
Number of subjects: 0
Study 6882699 — intervention group
Group type: EXPERIMENTAL
Intervention: Hostility
Number of subjects: 0
Study 31229990 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg daily for 24 months
Number of subjects: 228
Study 31229990 — intervention group
Group type: COMPARATOR
Intervention: Famotidine 40 mg daily for 24 months
Number of subjects: 228
Study 29445178 — intervention group
Group type: EXPERIMENTAL
Intervention: Clostridium butyricum (CB)
Number of subjects: 200
Study 29445178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 27792396 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (1,500 mg/day of DHA-enriched oil)
Number of subjects: 57
Study 27792396 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1,500 mg/day of sunflower oil)
Number of subjects: 57
Study 24694667 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 754
Study 24694667 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 754
Study 24694667 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined SES and EES
Number of subjects: 754
Study 24694667 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 754
Study 22853818 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous artesunate (AS) 2 mg/kg
Number of subjects: 24